GlassScriptPhysician profile
Karl E Anderson
NPI 1487713277
$41,111.19
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $8,266 · 2021: $5,750 · 2022: $653 · 2024: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $580.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $36,032.29 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $3,830.27 | 2020-2022 | |
| Tanabe Pharma America, INC. | $604.02 | 2022-2024 | |
| Eusa Pharma (US) LLC | $256.57 | 2022 | |
| Horizon Therapeutics Plc | $141.08 | 2022 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $115.26 | 2020 | |
| Abbvie INC. | $105.22 | 2019 | |
| Ethicon US, LLC | $26.48 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.